Author: sharmila

We're pleased to announce that Cure EB is joining three other EB charities to fund the clinical development of a new anti-fibrotic drug called TXA127. Click to read press release from Constant Pharmaceuticals.  ...

Scientists at the Sidney Kimmel Cancer Center at Jefferson University have discovered the cause of aggressive skin cancers in Recessive Dystrophic Epidermolysis Bullosa (RDEB) Click to see report from Jefferson University...

Krystal Biotech have announced that the first patient has been dosed in the Phase 1/2 clinical trial of its drug, KB103, for the treatment of dystrophic epidermolysis bullosa (DEB). The Phase 1/2 trial at Stanford University is a single-centre, open-label, placebo-controlled study conducting an intra-subject comparison...

A seven year old boy with Junctional Epidermolysis Bullosa child received genetically modified skin grafts and almost two years later his skin is functioning as normal. Skin cells were taken from Hassan in 2015 and genetically modified by a group of researchers. The cells were...

Lenticol -M Mesenchymal Stromal Cells engineered to express Collagen VII for the treatment of RDEB Dr Waseem Qasim, Professor J McGrath, Francesco Dazzi Further info A trial is currently underway to test the ability of fibroblasts to provide collagen VII in the skin of patients with...